uniQure N.V. Defined Contribution Plan, Cost
uniQure N.V. (QURE) reported Defined Contribution Plan, Cost of $1.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-02
- uniQure N.V. defined contribution plan, cost for fiscal 2025 was $1.80M, a 33.33% decline from fiscal 2024.
- uniQure N.V. defined contribution plan, cost for fiscal 2024 was $2.70M, a 25.00% decline from fiscal 2023.
- uniQure N.V. defined contribution plan, cost for fiscal 2023 was $3.60M, a 33.33% increase from fiscal 2022.
- uniQure N.V. defined contribution plan, cost for fiscal 2022 was $2.70M.
| Period end | Defined Contribution Plan, Cost 12 month |
|---|---|
| 2025-12-31 | $1.80M 10-K · filed 2026-03-02 |
| 2024-12-31 | $2.70M 10-K · filed 2026-03-02 |
| 2023-12-31 | $3.60M 10-K · filed 2026-03-02 |
| 2022-12-31 | $2.70M 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |